一种猴痘四价mRNA疫苗在小鼠中诱导出针对致死性痘苗病毒攻击的持续保护性免疫。
An mpox quadrivalent mRNA vaccine elicits sustained and protective immunity in mice against lethal vaccinia virus challenge.
作者信息
Li Entao, Yang Qiyuan, Xie Wenyu, Gong Qizan, Guo Xiaoping, Zhou Jinge, Zhang Jiachen, Chuai Xia, Wang Yucai, Chiu Sandra
机构信息
Department of Laboratory Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
出版信息
Emerg Microbes Infect. 2025 Dec;14(1):2447619. doi: 10.1080/22221751.2024.2447619. Epub 2025 Jan 22.
Assessing the long-term efficacy of MPXV vaccine candidates is crucial for the global response to the ongoing mpox epidemic. Built upon our previous study of the mpox quadrivalent mRNA vaccine, herein we reported that MPXV-1103 could elicit sustained humoral and cellular immunity in mice, including the induction of MPXV A35/B6/A29/M1-specific IgG antibodies, VACV neutralizing antibodies and activated cytotoxic CD8T cells, which provides 100% protection against lethal VACV challenge even at 280 days after the first vaccination. Our results provide critical insights for orthopoxvirus vaccine development.
评估猴痘候选疫苗的长期疗效对于全球应对当前的猴痘疫情至关重要。基于我们之前对猴痘四价mRNA疫苗的研究，在此我们报告称，MPXV-1103可在小鼠中引发持续的体液免疫和细胞免疫，包括诱导猴痘A35/B6/A29/M1特异性IgG抗体、痘苗病毒中和抗体以及激活的细胞毒性CD8T细胞，即使在首次接种后280天，也能提供100%抵御致死性痘苗病毒攻击的保护。我们的结果为正痘病毒疫苗的开发提供了关键见解。
Zotero 插件